How the new Wegovy tablets work, who they may be suitable for, and what we know so far.
This page provides educational information about investigational treatments currently in development. Numan does not currently prescribe Wegovy tablets.
What is it: an oral form of semaglutide, a GLP-1 receptor agonist used to support weight management.
Availability: Wegovy tablets aren't currently licensed in the UK.
/ "A new way to conquer weight loss")
Wegovy tablets are an oral form of semaglutide, the same active ingredient used in Wegovy injections. Semaglutide is a GLP-1 receptor agonist, meaning it mimics the naturally occurring GLP-1 hormone involved in appetite and blood sugar regulation.1
Like injectable Wegovy, the tablet form is intended to be used alongside a reduced-calorie diet and increased physical activity.
The key difference is how the medication enters the body. Injections are administered once weekly under the skin, whereas tablets are taken once daily and absorbed through the digestive system.
Wegovy tablets became available in the United States in early 2026. They are not currently approved in the UK.
In a 64-week clinical trial involving 307 adults living with obesity, or are overweight with at least one weight-related condition, participants taking semaglutide tablets lost on average 14% of their starting body weight, while those taking placebo lost on average 2.4%.1
These results, shown in the table, were achieved alongside lifestyle changes including dietary adjustments and increased physical activity.1 As with all weight loss treatments, individual results varied.1
| Weight loss achieved | Semaglutide tablets | Placebo |
|---|---|---|
| ≥5% body weight loss | 76% | 31% |
| ≥10% body weight loss | 60% | 14% |
| ≥15% body weight loss | 47% | 6% |
| ≥20% body weight loss | 28% | 3% |
Wegovy tablets are not currently available in the UK.
Before becoming available, they would need approval from the Medicines and Healthcare products Regulatory Agency (MHRA). If approved, further guidance from NICE would determine NHS availability.
While some estimates suggest availability could be considered in late 2026, there is no confirmed timeline. At present, Wegovy injections remain the only semaglutide formulation licensed for weight management in the UK.
Although Wegovy tablets and injections contain the same active ingredient, clinical data suggests that injectable semaglutide has demonstrated greater average weight loss in obesity trials. Likewise, prominent trials of other anti obesity medications also show superior outcomes to the new Wegovy tablet.1-3
*Results are based on separate clinical trials and cannot be directly compared. Results from the appropriate studies (references 1-3) are shown in the table.
| Treatment | Formulation | Study duration | Average weight loss |
|---|---|---|---|
| Semaglutide tablet (25mg daily) | Tablet | 64 weeks | 14% |
| Wegovy (semaglutide 2.4mg weekly) | Injection | 68-72 weeks | 21% |
| Tirzepatide 5mg weekly | Injection | 72 weeks | 15% |
| Tirzepatide 10mg weekly | Injection | 72 weeks | 19.5% |
| Tirzepatide 15mg weekly | Injection | 72 weeks | 20.9% |
| Placebo (tablet studies) | Tablet | 64 weeks | 2.4% |
| Placebo (tirzepatide trial) | Injection comperator | 72 weeks | 3.1% |
Numan does not currently prescribe Wegovy tablets, and they are not available through our services.
However, we closely monitor emerging clinical data and regulatory developments. If oral semaglutide is approved in the UK, they would undergo careful clinical review before being incorporated into any treatment pathway.
In the meantime, Numan provides access to licensed, MHRA-approved weight loss treatments alongside structured clinical supervision, regular monitoring, and behavioural support. If new therapies become available in the future, being under ongoing clinical care ensures you are in the strongest position to discuss next steps safely and appropriately.
Wharton S, Lingvay I, Bogdanski P, Duque do Vale R, Jacob S, Karlsson T, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. N Engl J Med. 2025;393(11):1077–87.
Chao AM, Tronieri JS, Amaro A, Wadden TA. Semaglutide for the treatment of obesity. Trends Cardiovasc Med. 2023;33(3):159–66
Hamza M, Papamargaritis D, Davies MJ. Tirzepatide for overweight and obesity management. Expert Opin Pharmacother. 2025;26(1):31–49.
Answer a few simple questions to get the treatment you need.
Updated:
/ "Eva")
